However, although there is also a close relationship between Aβ neurotoxicity, loss of Wnt signaling and PPARγ function in the pathogenesis of several neurological disorders, including AD, Miller et al. (2011) by reviewing some clinical studies suggested that rosiglitazone, a PPARγ agonist, should not be used as a therapy for AD, possibly at middle stages of AD (12-16). Here, PPARG is linked to nervous system disorder.